Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

APVO - Aptevo Therapeutics Inc


IEX Last Trade
0.35
-0.004   -1.086%

Share volume: 170,555
Last Updated: Fri 30 Aug 2024 08:21:25 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.35
0.00
-1.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
10%
Profitability 0%
Dept financing 13%
Liquidity 45%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
-10.69%
1 Month
-10.04%
3 Months
-50.38%
6 Months
-94.75%
1 Year
-98.04%
2 Year
-99.77%
Key data
Stock price
$0.35
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.28 - $21.56
52 WEEK CHANGE
-$0.98
MARKET CAP 
3.391 M
YIELD 
N/A
SHARES OUTSTANDING 
9.420 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$162,932
AVERAGE 30 VOLUME 
$272,608
Company detail
CEO:
Region: US
Website: http://aptevotherapeutics.com/
Employees: 59
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.

Recent news